Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 34, Issue 11, 2016, Pages 1223-1230

  Brambilla, Elisabeth ^a,b   Le Teuff, Gwénaël ^c,d   Marguet, Sophie ^c,d   Lantuejoul, Sylvie ^a,b   Dunant, Ariane ^c,d   Graziano, Stephen ^f   Pirker, Robert ^g   Douillard, Jean Yves ^e   Le Chevalier, Thierry ^c,d   Filipits, Martin ^g   Rosell, Rafael ⁱ   Kratzke, Robert ^j   Popper, Helmut ^h   Soria, Jean Charles ^c,d   Shepherd, Frances A ^k,l   Seymour, Lesley ^m   Tsao, Ming Sound ^k,l  

^a Institut Albert Bonniot Institut National   (France)

^b HÔPITAL MICHALLON   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UMR INSERM U892 CNRS 6299   (France)

^f SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^j UNIVERSITY OF MINNESOTA   (United States)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

^m QUEEN S UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NAVELBINE; PLATINUM; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; DEATH; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR LYMPHOCYTIC INFILTRATION; ADJUVANT CHEMOTHERAPY; AGED; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; TUMOR ASSOCIATED LEUKOCYTE; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS;

EID: 84966270857     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.0970     Document Type: Article

References (46)

1. Kataki A, Scheid P, Piet M, et al: Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 140:320-328, 2002
2. Ruffini E, Asioli S, Filosso PL, et al: Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 87:365-371, discussion 371-372, 2009
3. Wakabayashi O, Yamazaki K, Oizumi S, et al: CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 94:1003-1009, 2003
4. Johnson SK, Kerr KM, Chapman AD, et al: Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 27:27-35, 2000
5. Hiraoka K, Miyamoto M, Cho Y, et al: Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94:275-280, 2006
6. Gooden MJM, De Bock GH, Leffers N, et al: The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br J Cancer 105:93-103, 2011
7. Dieu-Nosjean M-C, Antoine M, Danel C, et al: Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26:4410-4417, 2008
8. Shimizu K, Nakata M, Hirami Y, et al: Tumorinfiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 5:585-590, 2010
9. Petersen RP, Campa MJ, Sperlazza J, et al: Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107:2866-2872, 2006
10. Horne ZD, Jack R, Gray ZT, et al: Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A nonsmall-cell lung cancer. J Surg Res 171:1-5, 2011
11. Kilic A, Landreneau RJ, Luketich JD, et al: Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res 167:207-210, 2011
12. Schalper KA, Brown J, Carvajal-Hausdorf D, et al: Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst 107:dju435, 2015
13. Schalper KA, Velcheti V, Carvajal D, et al: In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 20:2773-2782, 2014
14. Loi S, Sirtaine N, Piette F, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:860-867, 2013
15. Pagè s F, Berger A, Camus M, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654-2666, 2005
16. Adams S, Gray RJ, Demaria S, et al: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959-2966, 2014
17. Loi S, Michiels S, Salgado R, et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol 25:1544-1550, 2014
18. Di Caro G, Bergomas F, Grizzi F, et al: Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res 20: 2147-2158, 2014
19. Galon J, Costes A, Sanchez-Cabo F, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964, 2006
20. Nedergaard BS, Ladekarl M, Nyengaard JR, et al: A comparative study of the cellular immune response in patientswith stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol Oncol 108:106-111, 2008
21. Piersma SJ, Jordanova ES, Van Poelgeest MIE, et al: High number of intraepithelial CD8+ tumorinfiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 67: 354-361, 2007
22. Shi J-Y,Gao Q,Wang Z-C, et al:Margin-infiltrating CD20(+) B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma. Clin Cancer Res 19:5994-6005, 2013
23. Fukunaga A, Miyamoto M, Cho Y, et al: CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28:e26-e31, 2004
24. Schumacher K, Haensch W, Rö efzaad C, et al: Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 61:3932-3936, 2001
25. Pignon J-P, Tribodet H, Scagliotti GV, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26: 3552-3559, 2008
26. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004
27. Arriagada R, Dunant A, Pignon J-P, et al: Longterm results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 28:35-42, 2010
28. Douillard J-Y, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patientswith completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 7:719-727, 2006
29. Butts CA, Ding K, Seymour L, et al: Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10. J Clin Oncol 28:29-34, 2010
30. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352: 2589-2597, 2005
31. Strauss GM, Herndon JE II, Maddaus MA, et al: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043-5051, 2008
32. Travis WD, Brambilla E, Burke A, et al: WHO Classification of the Tumours of the Lung, Pleura, Thymus and Heart (ed 4). Lyon, France, IARC Press, 2015
33. Salgado R, Denkert C, Demaria S, et al: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol 26:259-271, 2015
34. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996
35. Lin DY, Wei LJ, Ying Z: Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 80:557-572, 1993
36. Collins GS, De Groot JA, Dutton S, et al: External validation of multivariable predictionmodels: A systematic review of methodological conduct and reporting. BMC Med Res Methodol 14:40, 2014
37. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391, 2005
38. Suzuki K, Kachala SS, Kadota K, et al: Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 17:5247-5256, 2011
39. Al-Shibli KI, Donnem T, Al-Saad S, et al: Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14:5220-5227, 2008
40. Howlader N, Noone A, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2010. Bethesda, MD, National Cancer Institute, 2013. http://seer.cancer.gov/csr/1975-2010
41. Koebel CM, Vermi W, Swann JB, et al: Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903-907, 2007
42. DuPage M, Cheung AF, Mazumdar C, et al: Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19:72-85, 2011
43. Dunn GP, Bruce AT, Ikeda H, et al: Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 3:991-998, 2002
44. Rousseaux S, Debernardi A, Jacquiau B, et al: Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med 5:186ra66, 2013
45. Pé guillet I, Milder M, Louis D, et al: High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res 74:2204-2216, 2014
46. Donnem T, Hald SM, Paulsen EE, et al: Stromal CD8+ T-cell density: A PRomising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res 21:2635-2643, 2015